Monopar Regulatory Tuesday, June 30, 2026 +0.50 Positive

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840

Monopar Therapeutics received Rare Pediatric Disease designation for ALXN1840 treating Wilson disease. This grants potential eligibility for a Pediatric Priority Review Voucher upon NDA approval.

View original filing at SEC.gov →

AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day